Louisiana State Employees Retirement System Has $13.84 Million Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Louisiana State Employees Retirement System lessened its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 2.6% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 165,100 shares of the biopharmaceutical company’s stock after selling 4,400 shares during the period. Louisiana State Employees Retirement System’s holdings in Gilead Sciences were worth $13,842,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. Outlook Wealth Advisors LLC boosted its position in shares of Gilead Sciences by 5.1% during the third quarter. Outlook Wealth Advisors LLC now owns 5,113 shares of the biopharmaceutical company’s stock valued at $429,000 after buying an additional 247 shares during the last quarter. Lake Street Advisors Group LLC boosted its holdings in Gilead Sciences by 2.7% during the 3rd quarter. Lake Street Advisors Group LLC now owns 17,774 shares of the biopharmaceutical company’s stock worth $1,490,000 after acquiring an additional 473 shares during the last quarter. Ballentine Partners LLC grew its stake in shares of Gilead Sciences by 73.9% in the 3rd quarter. Ballentine Partners LLC now owns 19,880 shares of the biopharmaceutical company’s stock worth $1,667,000 after acquiring an additional 8,451 shares in the last quarter. Tectonic Advisors LLC raised its holdings in shares of Gilead Sciences by 15.1% in the third quarter. Tectonic Advisors LLC now owns 75,706 shares of the biopharmaceutical company’s stock valued at $6,347,000 after purchasing an additional 9,958 shares during the last quarter. Finally, Cambridge Advisors Inc. bought a new position in shares of Gilead Sciences during the third quarter valued at about $222,000. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Trading Up 0.2 %

NASDAQ:GILD opened at $89.00 on Friday. Gilead Sciences, Inc. has a 1 year low of $62.07 and a 1 year high of $89.74. The stock’s fifty day moving average price is $82.46 and its two-hundred day moving average price is $73.42. The company has a debt-to-equity ratio of 1.18, a current ratio of 1.14 and a quick ratio of 0.95. The company has a market cap of $110.88 billion, a P/E ratio of 247.22, a P/E/G ratio of 2.98 and a beta of 0.18.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.61 by $0.40. Gilead Sciences had a return on equity of 29.34% and a net margin of 3.79%. The company had revenue of $6.95 billion for the quarter, compared to analyst estimates of $6.64 billion. As a group, analysts expect that Gilead Sciences, Inc. will post 3.78 EPS for the current year.

Gilead Sciences Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, September 27th. Stockholders of record on Friday, September 13th were given a $0.77 dividend. The ex-dividend date of this dividend was Friday, September 13th. This represents a $3.08 dividend on an annualized basis and a dividend yield of 3.46%. Gilead Sciences’s dividend payout ratio (DPR) is currently 855.56%.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the stock. JPMorgan Chase & Co. increased their price objective on shares of Gilead Sciences from $95.00 to $100.00 and gave the company an “overweight” rating in a research note on Wednesday, October 9th. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $70.00 price target on shares of Gilead Sciences in a research report on Monday, September 16th. Leerink Partners raised Gilead Sciences from a “market perform” rating to an “outperform” rating and boosted their price objective for the stock from $74.00 to $96.00 in a research report on Monday, October 21st. Leerink Partnrs upgraded Gilead Sciences from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 21st. Finally, Truist Financial lifted their target price on Gilead Sciences from $82.00 to $83.00 and gave the stock a “hold” rating in a research note on Thursday, August 15th. Ten equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $86.85.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, insider Johanna Mercier sold 29,357 shares of the firm’s stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $83.78, for a total transaction of $2,459,529.46. Following the sale, the insider now owns 78,127 shares in the company, valued at $6,545,480.06. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In other news, insider Johanna Mercier sold 29,357 shares of the business’s stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $83.78, for a total value of $2,459,529.46. Following the completion of the sale, the insider now owns 78,127 shares of the company’s stock, valued at approximately $6,545,480.06. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Merdad Parsey sold 2,000 shares of the stock in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $83.83, for a total value of $167,660.00. Following the sale, the insider now directly owns 100,189 shares of the company’s stock, valued at approximately $8,398,843.87. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 36,847 shares of company stock valued at $3,033,340. Corporate insiders own 0.16% of the company’s stock.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.